Spinal fusion surgeries are common procedures for treating a variety of spinal conditions, including degenerative spine disease, scoliosis, mechanical back pain, spinal stenosis, isthmic spondylolisthesis, cervical myelopathy, fractures, and tumors.^[@R1]--[@R3]^ With the advancement in fusion devices and the increase of aging population, the use of spinal fusion procedures have increased dramatically since 1990s in the United States (U.S.).^[@R3]--[@R5]^ During 1997 to 2003, the utilization of cervical, thoracolumbar, and lumbar fusions increased by 89%, 31%, and 134%, respectively.^[@R4]^ A study using the Nationwide Inpatient Sample estimated that between 1998 and 2008, 1,288,496 primary posterior lumbar fusions were performed.^[@R6]^ Among Medicare patients, the rate of complex spinal fusion procedures increased 15-fold between 2002 and 2007 resulting in increased life-threatening complications, higher readmission rate, and greater hospitalization costs.^[@R3]^ Despite the extensive efforts being made to reduce infections among patients undergoing spinal fusion surgeries, postsurgical infections including surgical site infections (SSIs) and blood stream infections (BSIs) still remain constant threats to these patients, especially to those receiving open posterior instrumented spinal fusion procedures.^[@R3],[@R7]--[@R10]^ With increasing emphasis on quality of care, reducing readmission rates and related costs has become an important component of health care reform in the U.S. Through establishing the Hospital Readmissions Reduction Program, the Centers for Medicare & Medicaid Services has been required to reduce payments to hospitals with excess readmissions since 2012.^[@R11]^

The risk of SSIs among patients undergoing instrumented spinal fusion surgeries was estimated to be 3.8% (median, 4.2%; range, 0.4--20%) based on 39 cohorts with a total of 28,628 patients.^[@R12]^ SSIs following spinal fusion surgeries can be superficial wound infection or invasive infection occurring in deep wound or organ space.^[@R13]^ Among all the pathogens causing postsurgical infections, *Staphylococcus aureus* (*S. aureus*) accounts for nearly half of all cases.^[@R8],[@R13],[@R14]^

SSIs and BSIs post spinal fusion surgeries were reported to be associated with worse clinical outcomes and significant cost increase compared with those without such complications.^[@R15]--[@R18]^ However, prior studies had small sample size, were conducted in a single health care facility, or did not focus specifically on *S. aureus*, the most common pathogen. For example, Kuhns *et al*^[@R18]^ reported that deep wound infection among 22 patients undergoing dorsal cervical fusion was associated with an average of \$12,619 higher cost than those without such infections. To better understand hospital resource utilization and costs related to postsurgical *S. aureus* infections among patients undergoing elective posterior instrumented spinal fusion surgeries in the U.S., use of data from large hospital discharge database would be beneficial.

This study aimed to assess the cost and hospital resource utilization related to postsurgical *S. aureus* SSIs and BSIs during 180-day follow-up period post elective, posterior, instrumented spinal fusion surgeries between 2010 and 2015 using data from 129 U.S. hospitals that consistently submitted microbiology data to the Premier Healthcare Database (PHD).

MATERIALS AND METHODS
=====================

Study Design, Data Source, and Participants
-------------------------------------------

A retrospective cohort study using de-identified PHD data was conducted. The PHD is a complete census of inpatient and hospital-based outpatient visits from over 700 hospitals across all 50 states and contains 20% of all hospital discharges in the U.S. since 2000. PHD data are extracted from standard hospital discharge files and include patients' demographics, disease status, and information on date-stamped billed services in patients' daily service records. Patients can be tracked across visits within facilities with a unique identifier.^[@R19],[@R20]^ About 25% of participating hospitals voluntarily contribute microbiology data to the PHD.

PHD data are HIPAA compliant according to 45 CRF 46.101(b)(4) and 45 CRF 164.506(d)(2)(ii)(B).

Patients who met all of the following inclusion criteria and none of the exclusion criteria were included. Inclusion criteria included (1) aged ≥ 18 years at time of index surgery; (2) had a principal/secondary ICD-9-CM procedure code for posterior instrumented spinal fusion surgeries including 81.01, 81.03, 81.05, 81.07, 81.08, 81.31, 81.33, 81.35, 81.37, or 81.38 during index hospitalization; (3) index hospitalization was elective; (4) was admitted between January 01, 2010, and June 30, 2015, to a qualifying hospital that submitted consistent microbiology data during the 12 months before and 6 months post index surgery. Exclusion criteria included (1) had a major surgery as defined by the National Healthcare Safety Network (NHSN) procedures done between index surgery and the positive culture;^[@R21]^ (2) had a positive *S. aureus* culture from a normally sterile site such as blood or cerebral spinal fluid (CSF) collected during the 12 months before or 2 days post index surgery; and (3) had the following infections present at admission of the index hospitalization: BSIs, SSI deep and organ/space infections, osteomyelitis, vertebral disc space infection, meningitis, and intra-abdominal infections defined by ICD-9-CM diagnosis codes.

Study Variables
---------------

Main exposure variable was infection status during the 180-day follow-up period. Three infection status groups were identified: any *S. aureus* infection, invasive *S. aureus* infection, and no *S. aureus* infection. Any *S. aureus* infection referred to having nonsurveillance culture positive for *S. aureus* (including both invasive and superficial infections). Invasive *S. aureus* infection was defined as having culture-confirmed BSI, deep SSI, or organ/space SSI. Specifically, BSI was defined as having a positive blood culture for *S. aureus* or having a positive nonblood nonsurveillance *S. aureus* culture and having one of the following ICD-9-CM codes: 038.11 (Methicillin-susceptible *S. aureus* septicemia), 038.12 (Methicillin-resistant *S. aureus* septicemia), 790.7 (bacteremia), and 038.10 (*Staphylococcal septicemia*, unspecified). Deep SSI was defined as (1) having a wound culture positive for *S. aureus* together with one of the following reoperation posterior spinal fusion specific ICD-9-CM procedure codes: 03.02, 03.09, 03.4, 77.19, 77.49, 77.69, 78.69, 80.09, 80.39, or one of the reoperation nonspecific ICD-9-CM procedure codes: 81.07, 81.62, 81.63, 81.64, 38.97, 81.35, 81.37, 81.38, 81.39, 83.02, 83.09, 83.14, 83.44, 83.45, 84.51, 86.04, 86.22; or (2) having a deep wound culture positive for *S. aureus*. Organ/Space SSI was defined as having a CSF culture positive for *S. aureus* or having a positive culture for *S. aureus* from a qualified specimen (*e.g.*, body fluid culture, tissue culture) together with an ICD-9-CM diagnosis codes of 730.0x, 730.2x, 324.1, 324.9, 996.66, 996.67, 567.xx, and 320.3 during the same hospitalization. No *S. aureus* infection group included patients who did not have any culture-confirmed *S. aureus* infections. ICD code descriptions were listed in Appendix A, <http://links.lww.com/BRS/B395>.

Main outcomes included total and variable hospitalization costs, hospital length of stay, number and risk of readmission, and discharge status for the last hospital admission during follow-up. Variable cost was captured as directly reported by the hospitals, which typically includes cost that are deemed directly related to patient\'s clinical care (*e.g.*, salaries for clinical staff, cost of supplies, and/or medications).

Patient and clinical characteristics that were assessed included sex, age, race/ethnicity, insurance type, level of fusion (single *vs*. multilevel), diabetic status, surgical history, year, type, and location of index surgery. Type of index surgery was categorized as fusion (Cervical: 81.01, 81.03; Thoracolumbar/Lumbar: 81.05, 81.07, 81.08), refusion (Cervical: 81.31, 81.33; Thoracolumbar/Lumbar: 81.35, 81.37, or 81.38), and both fusion and refusion (having codes from both of the above categories). Fusion categories were mutually exclusive. Charlson Comorbidity Index (CCI) was assessed using ICD-9-CM diagnosis codes at index hospitalization using Deyo algorithm^[@R22]^ with Premier modifications.^[@R23]^ Hospital characteristics included hospital size, teaching status, population served (rural *vs*. urban), and region.

Statistical Methods
-------------------

Continuous data were expressed as mean, standard deviation, median, interquartile range, and range. Categorical data were expressed as counts and percentages of patients in each category. Chi-square tests were used for testing statistical differences between infection and no infection groups for categorical variables. *T*-test or Wilcoxon Rank Sum test was used for testing differences in continuous variables between comparison groups. Cost estimates were adjusted to 2015 U.S. dollars based on Consumer Price Index for urban consumers for hospital and related services.^[@R24]^

Crude means were reported for cost variables by infection status. Generalized linear regression modeling was used to compare differences in cost between infection and no infection groups adjusting for known confounders, including age, race, fusion type, fusion level, CCI, hospital size, teaching status, and hospital region. Each model was bootstrapped using 1000 replicates with replacement to account for skewness in the data. For each group, mean, 2.5% and 97.5% estimates were used to determine the average costs and 95% confidence intervals (95% CIs).

Negative binomial regression modeling was used to compare total length of stay and number of readmissions and Poisson regression modeling with robust error variance analysis was used to compare risk of readmission adjusting for known confounders.

Analyses were performed using SAS/STAT software, Version 9.4 of the SAS system \[Copyright (2016) SAS Institute Inc., Cary, NC). Statistical significance level was assessed at 0.05 alpha level.

RESULTS
=======

Patient and Hospital Characteristics
------------------------------------

A total of 13,212 patients were included in the final analysis: 294 (2.22%) with any *S. aureus* infection, including 151 (1.14%) with invasive *S. aureus* infection and 12,918 with no *S. aureus* infection (Figure [1](#F1){ref-type="fig"}). Most patient characteristics were comparable between infection and no infection groups (Table [1](#T1){ref-type="table"}). Compared with no *S. aureus* infection group, a higher percentage of patients in invasive group had multilevel fusion (81.46% *vs*. 69.25%, *P* = 0.0012). Any infection group had similar distribution in all but race variables with a higher percentage of white patients than in no *S. aureus* infection group. There was significant difference in geographical location and hospital size between invasive and no *S. aureus* infection groups (Table [1](#T1){ref-type="table"}).

![*Staphylococcus aureus* infection post spinal fusion surgery study patient selection flow chart.](brs-44-637-g001){#F1}

###### 

Baseline Patient and Hospital Characteristics by Infection Status

  Characteristics                                            No *S. aureus* Infection (Comparison Group)   Invasive *S. aureus* Infection   *P* (Invasive *vs*. No Infection)   Any *S. aureus* Infection   *P* (Any *vs*. No Infection)
  ---------------------------------------------------------- --------------------------------------------- -------------------------------- ----------------------------------- --------------------------- ------------------------------
  Total number of unique patients                            12,918                                        151                                                                  294                         
  **Patient characteristics**                                                                                                                                                                               
  Male sex (%)                                               42.69                                         36.42                            0.2993                              42.86                       0.9872
  Mean age in yrs (Std. Dev.)                                60.97 (13.51)                                 60.61 (13.81)                    0.7793                              60.24 (13.80)               0.3697
  Race, white (%)                                            81.43                                         82.12                            0.8280                              87.41                       0.0089
  Multiple level of fusion (%)                               69.25                                         81.46                            0.0012                              73.13                       0.1540
  Type of index surgery (%)                                                                                                                                                                                 
   Fusion                                                    92.26                                         91.39                            0.0972                              93.54                       0.1129
   Refusion                                                  5.05                                          3.31                                                                 2.72                        
   Both fusion and refusion                                  2.69                                          5.30                                                                 3.74                        
  Year of index surgery (%)                                                                                                                                                                                 
   2010                                                      24.34                                         30.46                            0.4521                              23.13                       0.1726
   2011                                                      20.04                                         21.85                                                                26.19                       
   2012                                                      20.88                                         15.89                                                                20.07                       
   2013                                                      17.77                                         16.56                                                                17.01                       
   2014                                                      11.74                                         10.60                                                                9.18                        
   2015                                                      5.23                                          4.64                                                                 4.42                        
  Location of index surgery (%)                                                                                                                                                                             
   Thoracolumbar/lumbar                                      87.20                                         88.74                            0.3118                              88.44                       0.8023
   Cervical                                                  11.81                                         9.27                                                                 10.54                       
   Both cervical and thoracolumbar/lumbar                    0.99                                          1.99                                                                 1.02                        
  Had surgery during the 3 months before index surgery (%)   2.24                                          3.31                             0.3967                              1.70                        0.5323
  Prophylactic antibiotic use (%)                            98.07                                         96.69                            0.2219                              98.30                       0.7794
  **Hospital characteristics**                                                                                                                                                                              
  Hospital size (%)                                                                                                                                                                                         
   1--299 beds                                               32.47                                         23.84                            \< 0.001                            43.88                       \< 0.001
   300--499 beds                                             44.96                                         39.07                                                                35.03                       
   500+ beds                                                 22.57                                         37.09                                                                21.09                       
  Teaching hospital (%)                                      42.88                                         50.33                            0.0659                              34.01                       0.0024
  Population served, rural (%)                               4.47                                          4.64                             0.9203                              2.72                        0.1502
  Region of hospital (%)                                                                                                                                                                                    
   Midwest                                                   15.81                                         21.85                            0.0206                              12.93                       \< 0.001
   Northeast                                                 20.84                                         21.85                                                                15.65                       
   South                                                     37.35                                         40.40                                                                56.46                       
   West                                                      26.00                                         15.89                                                                14.97                       

No *S. aureus* infection group is the comparison group for both invasive and any *S. aureus* infection groups.

Baseline Charlson Comorbidities
-------------------------------

Only prevalence of diabetes without chronic complications varied significantly between groups (Table [2](#T2){ref-type="table"}). A higher percentage of patients in invasive (32.45%, *P* \< 0.001) and any (26.53%, *P* = 0.0074) infection groups had diabetes without chronic complications during the index hospitalization than no *S. aureus* infection group (20.39%). Patients in invasive infection group had higher mean CCI score than those in no *S. aureus* infection group (1.09 *vs*. 0.83, *P* = 0.0006).

###### 

Baseline Patient Comorbidities by Infection Status

  Variables                                                   No *S. aureus* Infection (Comparison Group)   Invasive *S. aureus* Infection   *P* (Invasive *vs*. No Infection)   Any *S. aureus* Infection   *P* (Any *vs*. No Infection)
  ----------------------------------------------------------- --------------------------------------------- -------------------------------- ----------------------------------- --------------------------- ------------------------------
  Total number of unique patients                             12,918                                        151                                                                  294                         
  Type of comorbidities (%)                                                                                                                                                                                  
   Myocardial infarction                                      4.34                                          5.96                             0.3306                              4.42                        0.9424
   Congestive heart failure                                   3.51                                          5.96                             0.1045                              3.40                        0.9226
   Peripheral vascular                                        2.80                                          4.64                             0.2059                              3.40                        0.5392
   Cerebrovascular disease                                    2.14                                          1.99                             1.0000                              2.04                        0.9035
   Dementia                                                   0.63                                          0.66                             0.6200                              1.36                        0.1249
   Chronic pulmonary disease                                  20.09                                         23.84                            0.2529                              18.71                       0.5588
   Rheumatic disease                                          4.30                                          5.30                             0.5501                              4.76                        0.7024
   Peptic ulcer disease                                       0.63                                          0.66                             0.6155                              0.68                        0.7081
   Mild liver disease                                         0.35                                          0.66                             0.4146                              0.34                        1.0000
   Diabetes without chronic complication                      20.39                                         32.45                            \< 0.001                            26.53                       0.0099
   Diabetes with chronic complication                         2.93                                          1.32                             0.3315                              1.02                        0.0529
   Hemiplegia or paraplegia                                   0.55                                          1.99                             0.0541                              1.02                        0.2274
   Renal disease                                              5.41                                          5.30                             0.9513                              4.08                        0.3179
   Moderate or severe liver disease                           0.11                                          0.66                             0.1601                              0.34                        0.2866
   Any malignancy[^\*^](#TF2-1){ref-type="table-fn"}          1.18                                          1.99                             0.2662                              1.02                        1.0000
   Metastatic solid tumor[^†^](#TF2-2){ref-type="table-fn"}   0.53                                          0.66                             0.5525                              0.34                        1.0000
   AIDS/HIV                                                   0.07                                          0.00                             0.7456                              0.00                        0.6507
  Mean CCI Score (Std. Dev.)                                  0.83 (1.23)                                   1.09 (1.28)                      0.0006                              0.83 (1.11)                 0.4500

No *S. aureus* infection group is the comparison group for both invasive and any *S. aureus* infection groups.

S. aureus indicates Staphylococcus aureus.

^\*^Including lymphoma and leukemia, not include malignant neoplasm of skin.

^†^Mutually exclusive with any malignancy group.

Unadjusted Analysis Results
---------------------------

All-cause 180-day readmission risk was 96.03% in invasive infection group, 54.76% in any infection group, and 19.18% in no *S. aureus* infection group (*P* \< 0.001) (Table [3](#T3){ref-type="table"}). Total length of hospital stay during index hospitalization and follow-up in invasive infection group was over three times that of no *S. aureus* infection group. Consistent with readmission risk and hospital length of stay observed, total and variable hospitalization costs were the highest in invasive group, followed by any and no *S. aureus* infection groups. Compared with no *S. aureus* infection group, a higher percentage of patients in invasive group were discharged to nursing homes, long-term care facilities, hospice, or other acute care facilities (49% *vs*. 32%) at their last hospital admission during follow-up (Table [3](#T3){ref-type="table"}).

###### 

Unadjusted Hospital Resource Utilization and Cost by Infection Status During the 180-day Follow-up Period

  Outcomes                                                     No *S. aureus* Infection (Comparison Group)   Invasive *S. aureus* Infection   *P* (Invasive *vs*. No Infection)   Any *S. aureus*^\*^ Infection   *P* (Any *vs*. No Infection)
  ------------------------------------------------------------ --------------------------------------------- -------------------------------- ----------------------------------- ------------------------------- ------------------------------
  Total number of unique patients                              12,918                                        151                                                                  294                             
  Mean number of all-cause readmission (Std. Dev.)             0.25 (0.59)                                   1.65 (0.99)                      \< 0.001                            0.90 (1.07)                     \< 0.001
  All-cause readmission rate (%)                               19.18                                         96.03                            \< 0.001                            54.76                           \< 0.001
  Total length of stay, days                                                                                                                                                                                      
   Mean                                                        6.24                                          21.26                            \< 0.001                            12.60                           \< 0.001
   STD                                                         6.74                                          18.79                                                                16.24                           
   Median                                                      4.00                                          17.00                                                                6.00                            
   IQR                                                         3, 7                                          9, 28                                                                3, 17                           
   Range                                                       1, 189                                        4, 121                                                               1, 121                          
  Total hospitalization cost (in 2015 U.S. dollars)                                                                                                                                                               
   Mean                                                        \$48,968                                      \$98,382                         \< 0.001                            \$68,460                        \< 0.001
   STD                                                         \$33,674                                      \$80,526                                                             \$67,982                        
   Median                                                      \$40,273                                      \$79,569                                                             \$49,516                        
   IQR                                                         \$27,747, \$59,812                            \$53,122, \$113,779                                                  \$28,378, \$83,397              
   Range                                                       \$444,026                                     \$586,069                                                            \$591,722                       
  Total variable hospitalization cost (in 2015 U.S. dollars)                                                                                                                                                      
   Mean                                                        \$31,351                                      \$57,144                         \< 0.001                            \$42,387                        \< 0.001
   STD                                                         \$22,578                                      \$45,848                                                             \$38,289                        
   Median                                                      \$25,595                                      \$43,983                                                             \$31,580                        
   IQR                                                         \$17,225, \$38,584                            \$31,559, \$67,127                                                   \$20,445, \$51,565              
   Range                                                       \$364,867                                     \$388,928                                                            \$389,854                       
  Discharge status for latest inpatient admission (%)                                                                                                                                                             
   Home/Home health                                            68.00                                         50.99                            \< 0.001                            66.67                           0.1419
   Skilled nursing, hospice, rehabilitation centers            31.34                                         47.02                                                                32.31                           
   Transfer to another acute care hospital                     0.27                                          1.99                                                                 1.02                            
   Expired                                                     0.25                                          0.00                                                                 0.00                            
   Other/unknown                                               0.14                                          0.00                                                                 0.00                            

No *S. aureus* infection group is the comparison group for both invasive and any *S. aureus* infection groups.

S. aureus indicates Staphylococcus aureus.

Adjusted Analysis Results
-------------------------

After adjusting for confounders and using bootstrapping method, the mean number of 180-day all-cause readmissions was highest among invasive infection group and lowest among no *S. aureus* infection group (adjusted mean: 1.65 *vs*. 0.25, *P* \< 0.001) (Table [4](#T4){ref-type="table"}). Mean length of hospital stay during index hospitalization and 180-day follow-up period in invasive group was three times of that in no *S. aureus* infection group (adjusted mean: 20.98 *vs*. 6.77 days, *P* \< 0.001). The adjusted mean length of stay in the any infection group was two times of that in no *S. aureus* infection group (adjusted mean: 13.15 *vs*. 6.77 days, *P* \< 0.001). The adjusted mean of total hospitalization cost remained highest in invasive infection group (Mean: \$88,353, 95% CI: 78,907--100,893), followed by any infection group (Mean: \$64,356, 95% CI: 58,106--70,893), and lowest in no *S. aureus* infection group (Mean: \$47,366, 95% CI: 46,840--47,889) (Figure [2](#F2){ref-type="fig"}). The adjusted total variable hospitalization cost followed similar patterns and was highest among patients with invasive infection (Mean: \$50,966, 95% CI: 45,802--57,975), followed by any infection group (Mean: \$39,820, 95% CI: 36,199--43,673), and lowest in no *S. aureus* infection group (Mean: \$30,243, 95% CI: 29,918--30,592).

###### 

Multivariable Regression Analysis Results for Total and Variable Hospitalization Costs and Hospital Resource Utilization by Infection Status

  Hospitalization Cost                   Invasive *S. aureus* Infection   Any *S. aureus* Infection   No *S. aureus* Infection
  -------------------------------------- -------------------------------- --------------------------- --------------------------
  Total number of unique patients        151                              294                         12,918
  Total number of 180-day readmissions                                                                
   Adjusted mean                         1.65                             0.94                        0.25
   95% CI                                1.33--2.05                       0.78--1.14                  0.22--0.27
  Total length of stay, days                                                                          
   Adjusted mean                         20.98                            13.15                       6.77
   95% CI                                18.80--23.42                     12.07--14.33                6.54--7.01
  Total hospitalization cost                                                                          
   Mean                                  \$88,353                         \$64,356                    \$47,366
   95% CI                                \$78,907--\$100,893              \$58,106--\$70,893          \$46,840--\$47,889
  Total variable hospitalization cost                                                                 
   Mean                                  \$50,966                         \$39,820                    \$30,243
   95% CI                                \$45,802--\$57,975               \$36,199--\$43,673          \$29,918--\$30,592

\(1\) Bootstrapping was used in the modeling. Confounding variables adjusted in the models included age, race, fusion type, fusion level, Charlson Comorbidity Index, hospital size, teaching status, and hospital region. (2) Estimates for No *S. aureus* infection group were from modeling comparisons between invasive *S. aureus* and No *S. aureus* group. No *S. aureus* group is the reference group for each set of comparisons. (3) All cost calculation was adjusted to 2015 US dollars based on Consumer Price Index for all urban consumers for hospital and related services.

CI indicates confidence interval; *S. aureus*, *Staphylococcus aureus*.

![Adjusted mean hospitalization cost and 95% confidence interval by infection status. Solid black bar represents Invasive *S. aureus* Infection group, grey bar with line pattern represents Any Invasive *S. aureus* Infection group, and white bar with dot pattern represents No *S. aureus* Infection group. Note: The 95% confidence intervals for the No *S. aureus* infection group were too narrow to show up in the chart but they did not overlap with intervals of the other two infection groups for either total or variable cost.](brs-44-637-g002){#F2}

Compared with patients under 50 years, patients ≥75 years were twice as likely to get readmitted. Nonwhite patients and those with multilevel fusion, having both fusion and refusion surgeries during index hospitalization, having higher CCI, from medium size hospitals or hospitals in Midwest were more likely to get readmitted than their peers (Table [5](#T5){ref-type="table"}). After controlling confounders, the relative risk of 180-day all-cause readmission in invasive and any infection group was 2.15 times (95% CI: 2.06--2.25) and 1.70 times (95% CI: 1.61--1.80) that of no *S. aureus* infection group, respectively.

###### 

Multivariable Poisson Regression Modeling With Robust Error Variance Analysis Results for 180-day Readmission Risk

  Variable                         Model 1: Invasive *vs*. No*S. aureus* Infection   Model 2: Any *vs*. No*S. aureus* Infection               
  -------------------------------- ------------------------------------------------- -------------------------------------------- ----------- ------------
  Invasive *S. aureus* infection   2.15                                              2.06--2.25                                   N/A         N/A
  Overall *S. aureus* infection    N/A                                               N/A                                          1.70        1.61--1.80
  Age in yrs (%)                                                                                                                              
   18--49                          Reference                                         Reference                                    Reference   Reference
   50--64                          1.24                                              1.10--1.39                                   1.22        1.09--1.37
   65--74                          1.72                                              1.54--1.93                                   1.69        1.51--1.89
   75+                             2.06                                              1.82--2.32                                   2.04        1.81--2.30
  Race (%)                                                                                                                                    
   White                           Reference                                         Reference                                    Reference   Reference
   Nonwhite                        1.09                                              1.05--1.14                                   1.10        1.05--1.14
  Level of fusion (%)                                                                                                                         
   Single level                    Reference                                         Reference                                    Reference   Reference
   Multiple level                  1.17                                              1.13--1.22                                   1.18        1.13--1.23
  Type of index surgery (%)                                                                                                                   
   Fusion                          Reference                                         Reference                                    Reference   Reference
   Refusion                        1.11                                              0.95--1.29                                   1.11        0.95--1.30
   Both fusion and refusion        1.28                                              1.08--1.52                                   1.29        1.09--1.53
  Charlson Comorbidity Index       1.13                                              1.11--1.16                                   1.14        1.12--1.16
  Hospital size (%)                                                                                                                           
   1--299 beds                     0.80                                              0.75--0.85                                   0.78        0.73--0.82
   300--499 beds                   1.10                                              1.05--1.16                                   1.11        1.06--1.17
   500+ beds                       Reference                                         Reference                                    Reference   Reference
  Teaching status (%)                                                                                                                         
   Nonteaching hospital            Reference                                         Reference                                    Reference   Reference
   Teaching hospital               0.82                                              0.78--0.86                                   0.83        0.79--0.87
  Region of hospital (%)                                                                                                                      
   Midwest                         1.14                                              1.07--1.22                                   1.15        1.08--1.23
   Northeast                       1.00                                              0.92--1.09                                   1.01        0.93--1.11
   South                           1.03                                              0.97--1.08                                   1.00        0.95--1.06
   West                            Reference                                         Reference                                    Reference   Reference

Model 1 assessed the association between invasive *S. aureus* infection and 90-day readmission risk adjusting for all known confounders. Model 2 assessed the association between any *S. aureus* infection and 90-day readmission risk adjusting for all known confounders.

CI indicates confidence interval; S. aureus, Staphylococcus aureus.

DISCUSSION
==========

As one of the first studies using large national hospital discharge data to assess hospital resource utilization and cost related to culture-confirmed *S. aureus* infections post elective posterior instrumented spinal fusion surgeries, our study demonstrated that nearly all patients (96.03%) with invasive *S. aureus* infection had at least one readmission compared with 19.18% among no *S. aureus* infection group. After adjusting for confounders, invasive *S. aureus* infection was associated with a 115% increased risk of all-cause readmission during the 180-day follow-up period compared with no *S. aureus* infection group. Patients with invasive *S. aureus* infection usually need aggressive surgical debridement and prolonged antibiotic treatment, which often requires readmission.^[@R25]^ Using data from a single hospital, Schairer *et al*^[@R26]^ estimated that the reoperation rate for instrumented spinal fusion patients was 89.2%, which is consistent with the high readmission rate reported by our study.

When comparing hospital resource utilization between infection groups, our findings indicated that invasive and any *S. aureus* infection groups had an average of 14.21 and 6.38 more days of hospital stay during the index hospitalization and follow-up than no *S. aureus* infection group after adjusting for confounders. Pooled results from the study by Patel *et al*^[@R12]^ also indicated that patients with any SSI had longer length of stay (range, 7.1--19.3 days) than those without SSI (4.0--9.3 days).

Higher readmission risk and longer total hospital length of stay in invasive and any postsurgical *S. aureus* infection groups resulted in an average of \$40,987 and \$16,900 more total hospitalization cost compared with no *S. aureus* infection group over the 180-day follow-up period, respectively. The infection groups also had higher total variable hospitalization cost than the no infection group, which indicated that patients with postsurgical *S. aureus* infections consume more clinical resources in the hospital than those without such infections. Although the absolute amount of extra cost estimated by our study differs from estimates of previous studies due to different cost variable definitions and study populations, the general association between postsurgical infection and higher health care cost remains consistent across studies.^[@R18],[@R27]^ Because this is a study using existing hospital discharge data, we were only able to assess the hospital burdens of *S. aureus* infections post target spinal fusion surgeries. The overall burden to the healthcare system and to the society would be even more substantial.

Compared with studies published before, this study has multiple strengths. First, we used data collected from 129 hospitals nationwide, which is more representative than studies conducted in one single institution. The large sample size provided sufficient power to test differences in key outcomes between comparison groups. Second, all cases were culture-confirmed, which is more accurate than cases identified by ICD diagnosis codes only. Third, we included not only invasive SSI but also BSI and noninvasive infections in the analysis, which provided a broad spectrum of *S. aureus* infections for analysis while further segmenting the infections by invasiveness (invasive and any *S. aureus* infection). Finally, on the basis of hospital reporting, variable hospitalization costs could be assessed, which may reflect attributable clinical resource utilization more accurately than total hospitalization cost.^[@R28]^

This study also has limitations. First, although we have high-quality cost and clinical data, we miss some clinical details that may help differentiate superficial from invasive *S. aureus* infections. This limited our ability to assess the impact of superficial infections separately. Second, because PHD only captures readmissions or outpatient visits to the same hospitals where the index surgeries occurred, the number of *S. aureus* infections, number of readmissions, and costs may be underestimated. This limitation is expected to be nondifferential across infection groups. Third, we only focused on *S. aureus* infections among patients with posterior instrumented spinal fusion surgeries in this study. More research is needed to study the impact of infections due to other pathogens and among patients with other types of spinal fusion surgeries.

In conclusion, our findings indicate that among patients undergoing elective, posterior, instrumented spinal fusion surgeries, *S. aureus* infections, especially invasive infections, are associated with significantly higher hospitalization cost, risk and number of all-cause readmissions, and total length of hospital stay during the 180-day follow-up period postindex surgery compared with patients experiencing no *S. aureus* infection. Reducing postsurgical *S. aureus* infection risk among these patients may reduce risk of readmission and economic burden. Although the effectiveness of many preoperative, intraoperative, and postoperative infection control measures on reducing SSIs have been studied, few have been proven effective with strong clinical evidence support based on guidelines from the World Health Organization and the Association for Professionals in Infection Control and Epidemiology.^[@R29],[@R30]^ The review by Agarwal *et al* on implant contamination and septic methods concluded that more research is needed to explore effective methods to prevent postsurgical infections among patients undergoing elective, posterior, instrumented spinal fusion surgeries.^[@R31]^Key Points*Staphylococcus aureus* infections post elective posterior instrumented spinal fusion surgeries, especially invasive infections, are associated with significantly higher hospitalization cost, length of stay, and 180-day risk of readmission compared with those with no such infection.The overall 180-day risk of any *Staphylococcus aureus* infection was estimated to be 2.22% and of invasive *Staphylococcus aureus* infection was estimated to be 1.14%.The substantial economic and clinical burden associated with postsurgical *Staphylococcus aureus* infections calls for more effective infection control measures to reduce such infections.
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